|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
11253522 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160309s2016 sz a ob 000 0 eng d |
| 005 |
20240624203655.7 |
| 015 |
|
|
|a GBB8N3354
|2 bnb
|
| 016 |
7 |
|
|a 019148588
|2 Uk
|
| 019 |
|
|
|a 944186070
|a 951973057
|a 985052694
|a 1005783602
|a 1011848464
|
| 020 |
|
|
|a 9783319278834
|q (electronic bk.)
|
| 020 |
|
|
|a 3319278835
|q (electronic bk.)
|
| 020 |
|
|
|a 3319278819
|q (print)
|
| 020 |
|
|
|a 9783319278810
|q (print)
|
| 020 |
|
|
|z 9783319278810
|q (print)
|
| 024 |
7 |
|
|a 10.1007/978-3-319-27883-4
|2 doi
|
| 035 |
|
|
|a (OCoLC)944183047
|z (OCoLC)944186070
|z (OCoLC)951973057
|z (OCoLC)985052694
|z (OCoLC)1005783602
|z (OCoLC)1011848464
|
| 035 |
|
9 |
|a (OCLCCM-CC)944183047
|
| 037 |
|
|
|a com.springer.onix.9783319278834
|b Springer Nature
|
| 040 |
|
|
|a GW5XE
|b eng
|e rda
|e pn
|c GW5XE
|d YDXCP
|d AZU
|d N$T
|d IDEBK
|d CDX
|d OCLCF
|d COO
|d EBLCP
|d UAB
|d OCLCQ
|d IAD
|d JBG
|d ICW
|d VT2
|d Z5A
|d ILO
|d ICN
|d OCLCQ
|d ESU
|d IOG
|d U3W
|d WYU
|d UKMGB
|d AU@
|d UKAHL
|d OCLCQ
|d UBY
|
| 049 |
|
|
|a MAIN
|
| 050 |
|
4 |
|a RM315
|
| 072 |
|
7 |
|a MMGW
|2 bicssc
|
| 072 |
|
7 |
|a MED105020
|2 bisacsh
|
| 245 |
0 |
0 |
|a Applied clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents /
|c Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen, editors.
|
| 264 |
|
1 |
|a Cham :
|b Adis,
|c 2016.
|
| 300 |
|
|
|a 1 online resource (xiv, 601 pages) :
|b illustrations (some color)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (SpringerLink, viewed March 9, 2016).
|
| 505 |
0 |
|
|a Section 1. General Pharmacokinetic and Pharmacodynamic Principles of Psychopharmacological Agents -- 1. Pharmacokinetic Properties -- 2. Pharmacodynamic Properties -- 3. PET Scan and Other Biomarkers -- 4. Population Pharmacokinetics -- 5. Drug Transporters (esp. Blood Brain Barrier) -- 6. Pharmacogenomics -- Section 2. Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Drug Classes -- 7. Antipsychotics -- oral typical agents, oral atypical agents, and long-acting injectable (LAI) antipsychotics -- 8. Mood Stabilizers -- 9. Antidepressants -- tricyclics, selective serotonergic reuptake inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase inhibitors, and other antidepressants -- 10. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 11. Opioid Analgesics -- 12. Stimulants and Other Non-Stimulants for ADHD -- 13. Cholinesterase Inhibitors and Other Antidementa Agents -- 14. Anti-Addiction Agents -- 15. Anesthetics -- Section 3. Clinically Significant Drug Interactions With Psychopharmacological Agents -- 16. Antipsychotics -- 17. Mood Stabilizers -- 18. Antidepressants -- 19. Benzodiazepines and Other Sedative Hypnotics/Anxiolytics -- 20. Opioid Analgesics -- 21. Stimulants and Other Non-Stimulants for ADHD -- 22. Cholinesterase Inhibitors and Other Antidementa Agents -- 23. Anti-Addiction Agents -- 24. Anesthetics.
|
| 520 |
|
|
|a This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto, and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents, nominally arranged intodifferent therapeutic categories and with reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions. Psychotropic medications from different categories are frequently prescribed together, or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology. Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions, isfrequently updated. However, with information presented on a host of different platforms, and in different formats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 650 |
|
0 |
|a Psychotropic drugs.
|0 http://id.loc.gov/authorities/subjects/sh85108528
|
| 650 |
|
0 |
|a Psychopharmacology.
|0 http://id.loc.gov/authorities/subjects/sh85108498
|
| 650 |
|
0 |
|a Pharmacokinetics.
|0 http://id.loc.gov/authorities/subjects/sh85100597
|
| 650 |
|
7 |
|a Pharmacology.
|2 bicssc
|
| 650 |
|
7 |
|a Psychopharmacology.
|2 bicssc
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmacokinetics.
|2 fast
|0 (OCoLC)fst01060250
|
| 650 |
|
7 |
|a Psychopharmacology.
|2 fast
|0 (OCoLC)fst01081659
|
| 650 |
|
7 |
|a Psychotropic drugs.
|2 fast
|0 (OCoLC)fst01081826
|
| 655 |
|
0 |
|a Electronic books.
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Jann, Michael W.,
|e editor.
|0 http://id.loc.gov/authorities/names/no2009078196
|
| 700 |
1 |
|
|a Penzak, Scott R.,
|e editor.
|
| 700 |
1 |
|
|a Cohen, Lawrence J.,
|e editor.
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319278810
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i b40307f6-5d1b-5d1f-aba0-83d645f8657e
|s 7f963167-ffb8-5e9e-ac26-24a37cb6e65f
|
| 928 |
|
|
|t Library of Congress classification
|a RM315
|l Online
|c UC-FullText
|u https://link.springer.com/10.1007/978-3-319-27883-4
|z Springer Nature
|g ebooks
|i 12535453
|
